NR1H4 and metabolic dysfunction-associated steatotic liver disease: FXR is a natural ligand for bile acids, and its agonists have been shown to promote the β-oxidation of fatty acids and inhibit several pathways involved in NAFLD, including bile acid synthesis, hepatic and intestinal recycling of bile acids, lipid synthesis, gluconeogenesis, and fatty acid uptake by hepatocytes (Carr and Reid, 2015; Xi and Li, 2020; Lin et al., 2022b).